https://www.selleckchem.com/pr....oducts/Belinostat.ht
3 h. In Group B, normal intraoperative hemostasis was reported in 63 patients (72.4%). CONCLUSIONS The results of this interim analysis suggest that idarucizumab is safe and effective for the reversal of dabigatran in Japanese patients in a real-world setting, and support the continued use of idarucizumab. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT02946931.The critical care environment drives huge volumes of data, and clinicians are tasked with quickly processing this data and responding to it urgently. The neurocritical c
Like
Comment
Share
